Notes | Project documents | Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Guidance | NICE

_{Please note that the timelines for this appraisal have now been confirmed by the company with the appraisal anticipated to begin during mid-January 2027 when we will write to you about how you can get involved.}